Oculome 面板检测:下一代测序诊断多种遗传性发育性眼病
本研究开发了一种覆盖429个已知眼病基因的下一代测序面板(oculome),并在277名0至16岁未确诊的发育性眼病患儿中评估其诊断率。总体确诊68/277例,不同表型亚组诊断率从8.2%到88.9%不等。该检测可诊断广泛的遗传性眼发育疾病,有望替代冗长昂贵的多学科评估并实现更快的靶向管理。
要点
- Oculome面板覆盖429个眼病基因,包含5个重叠虚拟亚组及视神经萎缩和复杂斜视相关基因。
- 在277例发育性眼病患儿中,总体分子确诊率为68/277,各表型亚组诊断率差异明显。
- 该检测有望替代多学科评估并支持更快靶向管理,但研究为单队列评估。
核心结论
- Oculome检测可诊断广泛的遗传性眼发育疾病,在多样眼部出生缺陷队列中使相当数量病例获得分子诊断。
研究设计与样本
- 诊断检测评估研究,纳入277名0至16岁无遗传诊断的非综合征或综合征发育性眼缺陷儿童。
- 采用Agilent SureSelect QXT靶向捕获对429个眼病相关基因进行平行高通量测序,疑似致病变异经双向Sanger测序确认。
主要发现
- 总体在277例样本中68例获得明确诊断,诊断率随表型亚组变化。
- MAC亚组诊断率8.2%(98例中8例),ASDA亚组24.8%(113例中28例),其他或综合征亚组37.5%(8例中3例)。
- RET亚组诊断率42.8%(49例中21例),先天性白内障及晶状体相关疾病亚组88.9%(9例中8例)。
- 测序覆盖目标1.77-Mb区域的99.5%达到超过30×读深。
关键数值与推荐
- Oculome设计覆盖429个已知眼病基因,分为ASDA(59基因)、MAC(86基因)、先天性白内障及晶状体相关(70基因)、视网膜营养不良(235基因)、白化病(15基因)5个重叠虚拟亚组,另含视神经萎缩和复杂斜视相关10基因。
临床怎么用
- 对于未确诊的发育性眼病患儿,可考虑使用Oculome面板检测以获取分子诊断。
- 检测结果可能替代冗长昂贵的多学科评估,并支持更快的靶向管理。
局限性
- 研究为单队列诊断检测评估,诊断率在不同表型亚组间差异较大,部分亚组样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop a comprehensive next-generation sequencing panel assay that screens genes known to cause developmental eye disorders and inherited eye disease and to evaluate its diagnostic yield in a pediatric cohort with malformations of the globe, anterior segment anomalies, childhood glaucoma, or a combination thereof. DESIGN: Evaluation of diagnostic test. PARTICIPANTS: Two hundred seventy-seven children, 0 to 16 years of age, diagnosed with nonsyndromic or syndromic developmental eye defects without a genetic diagnosis. METHODS: We developed a new oculome panel using a custom-designed Agilent SureSelect QXT target capture method (Agilent Technologies, Santa Clara, CA) to capture and perform parallel high-throughput sequencing analysis of 429 genes associated with eye disorders. Bidirectional Sanger sequencing confirmed suspected pathogenic variants. MAIN OUTCOME MEASURES: Collated clinical details and oculome molecular genetic results. RESULTS: The oculome design covers 429 known eye disease genes; these are subdivided into 5 overlapping virtual subpanels for anterior segment developmental anomalies including glaucoma (ASDA; 59 genes), microphthalmia-anophthalmia-coloboma (MAC; 86 genes), congenital cataracts and lens-associated conditions (70 genes), retinal dystrophies (RET; 235 genes), and albinism (15 genes), as well as additional genes implicated in optic atrophy and complex strabismus (10 genes). Panel development and testing included analyzing 277 clinical samples and 3 positive control samples using Illumina sequencing platforms; more than 30× read depth was achieved for 99.5% of the targeted 1.77-Mb region. Bioinformatics analysis performed using a pipeline based on Freebayes and ExomeDepth to identify coding sequence and copy number variants, respectively, resulted in a definitive diagnosis in 68 of 277 samples, with variability in diagnostic yield between phenotypic subgroups: MAC, 8.2% (8 of 98 cases solved); ASDA, 24.8% (28 of 113 cases solved); other or syndromic, 37.5% (3 of 8 cases solved); RET, 42.8% (21 of 49 cases solved); and congenital cataracts and lens-associated conditions, 88.9% (8 of 9 cases solved). CONCLUSIONS: The oculome test diagnoses a comprehensive range of genetic conditions affecting the development of the eye, potentially replacing protracted and costly multidisciplinary assessments and allowing for faster targeted management. The oculome enabled molecular diagnosis of a significant number of cases in our sample cohort of varied ocular birth defects.
引用
- Patel A, Hayward JD, Tailor V, et al. The Oculome Panel Test: Next-Generation Sequencing to Diagnose a Diverse Range of Genetic Developmental Eye Disorders. Ophthalmology. 2019. PMID: 30653986. doi:10.1016/j.ophtha.2018.12.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。